Matching articles for "Adstiladrin"
Intravesical Gemcitabine (Inlexzo) for Bladder Cancer (online only)
The FDA has approved Inlexzo , a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ , with or…
Med Lett Drugs Ther. 2025 Oct 27; 67(1740):e176-7 doi:10.58347/tml.2025.1740c
The FDA has approved Inlexzo , a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ , with or without papillary tumors. The Inlexzo system is placed into the bladder to deliver gemcitabine for 3 weeks.
In Brief: Anktiva for Bladder Cancer (online only)
Nogapendekin alfa inbakicept-pmln ( Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of…
Med Lett Drugs Ther. 2024 Jun 24; 66(1705):e105-6 doi:10.58347/tml.2024.1705e
Nogapendekin alfa inbakicept-pmln ( Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin) and the immune checkpoint inhibitor pembrolizumab (Keytruda) are also approved for the same indication.
In Brief: Adstiladrin – A Gene Therapy for Bladder Cancer (online only)
Nadofaragene firadenovec-vncg ( Adstiladrin – Ferring), an adenoviral vector-based gene therapy, has been approved by the FDA for treatment of adults with high-risk Bacillus Calmette-Guérin…
Med Lett Drugs Ther. 2023 Mar 6; 65(1671):e40-1 doi:10.58347/tml.2023.1671e
Nadofaragene firadenovec-vncg ( Adstiladrin – Ferring), an adenoviral vector-based gene therapy, has been approved by the FDA for treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. It is the first adenoviral vector-based gene therapy to be approved in the US for this indication. The immune checkpoint inhibitor pembrolizumab (Keytruda) was approved for the same indication in 2021.
